Released May 11, 2023, after the close
10-Q filed May 11, 2023, 41 days after period end · 0001140361-23-024180
Q1 2023 · 10-Q
Revenue$0.00$0.00 no prior Q1 2022 on fileno prior Q4 2022 on file
Net Income-$5.42M-$5.42M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$1.06-$1.06 N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit-$50,000—
Operating Income-$5,316,000N/M
Operating Cash Flow-$6,049,000N/M
Free Cash Flowderived-$6,049,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | $2.39M |
| Net Income | -$5.42M | -$9.38M | -$18.52M | -$1.02M |
| EPS Diluted | -$1.06 | -$3.50 | -$0.67 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR